Infectious Diseases
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative
Cidara conferred global rights to its novel antifungal to marketing partner, Mundipharma, while reacquiring a flu prophylaxis it licensed to J&J in 2021 and gaining $240m in new funding to back development.
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Key Activist Investor Throws Shade At Novavax Over COVID-19 Vaccines
Shah Capital Management said Novavax could tap the estimated 100 million Americans uncomfortable with mRNA vaccines, such as those from Pfizer/BioNTech and Moderna.
Abrysvo Data In Younger Adults Could Give Pfizer An Edge Over GSK
Pfizer plans to use the positive Phase III data in adults 18-59 to expand use of the RSV vaccine.
Basilea Buoyant As Antibiotic Finally Gets US Nod
Sales of the Swiss firm’s Zevtera are set to rocket after the beta-lactam antibiotic got approval from the US Food and Drug Administration. Now Basilea needs to sign up a commercial partner.
Why Global Pull Incentives Matter For AMR Drugs
The sustainability of drugs that protect against antimicrobial resistance is on the edge without proper pull incentive models on a global scale. GARDP, Shionogi and a physician focused on infectious diseases explained why at a recent briefing in Tokyo.
Moderna Touts mRNA Progress, Plus $750m From Blackstone To Back Its Flu Vaccine
Moderna still projects $4.5bn in R&D spending this year for its pipeline of 28 mRNA vaccines, including a COVID-19 vaccine with stronger immune response than Spikevax.
Novartis Measures Malaria Success On Impact Rather Than Money
The Swiss major’s global health chief Lutz Hegemann tells Scrip on a trip to Rwanda that being a profitable enterprise while helping to improve access to new and older therapies for those who need it most is the real measure of a successful business.
Will Pfizer/BioNTech And Moderna Stay Atop The COVID-19 Vaccine Market Forever?
BIO CEO panelist Rajeev Venkayya argued that the huge amount of investment in COVID-19 vaccines makes it possible for new players to challenge Comirnaty and Spikevax’s dominance.
GSK Counters Innoviva’s Gonorrhea Hit
Both groups have posted hits with similar novel antibiotics, and both have a lot riding on commercial success.
Moderna Prepares To Enter The RSV Vaccine Fray
Its mRNA-based RSV vaccine challenger has a more convenient administration than GSK and Pfizer’s frontrunners, but may not compete on durability of protection.
Tarsus Demonstrates Lotilaner’s Potential In Preventing Lyme Disease
Lotilaner, the active ingredient in Tarsus’s Demodex blepharitis drug Xdemvy, showed significant ability to kill ticks in a small Phase IIa study. Analysts call the Lyme program a likely out-licensing opportunity for Tarsus.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.